KR100799788B1 - 면역촉진성 올리고디옥시뉴클레오티드 - Google Patents

면역촉진성 올리고디옥시뉴클레오티드 Download PDF

Info

Publication number
KR100799788B1
KR100799788B1 KR20027016711A KR20027016711A KR100799788B1 KR 100799788 B1 KR100799788 B1 KR 100799788B1 KR 20027016711 A KR20027016711 A KR 20027016711A KR 20027016711 A KR20027016711 A KR 20027016711A KR 100799788 B1 KR100799788 B1 KR 100799788B1
Authority
KR
South Korea
Prior art keywords
monothiophosphate
monophosphate
vaccine composition
odn
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR20027016711A
Other languages
English (en)
Korean (ko)
Other versions
KR20030032964A (ko
Inventor
왈터 쉬미트
카렌 린그나우
카롤라 쉬엘라크
알레나 에그와에드
Original Assignee
인터셀 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0100000A external-priority patent/AT410173B/de
Application filed by 인터셀 아게 filed Critical 인터셀 아게
Publication of KR20030032964A publication Critical patent/KR20030032964A/ko
Application granted granted Critical
Publication of KR100799788B1 publication Critical patent/KR100799788B1/ko
Assigned to 발네마 오스트리아 게엠베하 reassignment 발네마 오스트리아 게엠베하 권리의 전부이전등록 Assignors: 인터셀 아게
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR20027016711A 2000-06-08 2001-06-07 면역촉진성 올리고디옥시뉴클레오티드 Expired - Lifetime KR100799788B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung
ATA1000/2000 2000-06-08
AT19732000 2000-11-23
ATA1973/2000 2000-11-23

Publications (2)

Publication Number Publication Date
KR20030032964A KR20030032964A (ko) 2003-04-26
KR100799788B1 true KR100799788B1 (ko) 2008-01-31

Family

ID=25608484

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20027016711A Expired - Lifetime KR100799788B1 (ko) 2000-06-08 2001-06-07 면역촉진성 올리고디옥시뉴클레오티드

Country Status (25)

Country Link
US (3) US8568742B2 (cg-RX-API-DMAC10.html)
EP (1) EP1296713B1 (cg-RX-API-DMAC10.html)
JP (2) JP5271471B2 (cg-RX-API-DMAC10.html)
KR (1) KR100799788B1 (cg-RX-API-DMAC10.html)
CN (1) CN1309418C (cg-RX-API-DMAC10.html)
AT (1) ATE249839T1 (cg-RX-API-DMAC10.html)
AU (2) AU8181201A (cg-RX-API-DMAC10.html)
BR (1) BRPI0111639B8 (cg-RX-API-DMAC10.html)
CA (1) CA2411575C (cg-RX-API-DMAC10.html)
CZ (1) CZ304195B6 (cg-RX-API-DMAC10.html)
DE (1) DE60100814T2 (cg-RX-API-DMAC10.html)
DK (1) DK1296713T3 (cg-RX-API-DMAC10.html)
ES (1) ES2206424T3 (cg-RX-API-DMAC10.html)
HU (1) HU228264B1 (cg-RX-API-DMAC10.html)
IL (2) IL152959A0 (cg-RX-API-DMAC10.html)
IS (1) IS1993B (cg-RX-API-DMAC10.html)
MX (1) MXPA02012010A (cg-RX-API-DMAC10.html)
NO (1) NO329492B1 (cg-RX-API-DMAC10.html)
PL (1) PL211036B1 (cg-RX-API-DMAC10.html)
PT (1) PT1296713E (cg-RX-API-DMAC10.html)
RU (2) RU2293573C2 (cg-RX-API-DMAC10.html)
SI (1) SI1296713T1 (cg-RX-API-DMAC10.html)
SK (1) SK287689B6 (cg-RX-API-DMAC10.html)
TR (1) TR200302015T4 (cg-RX-API-DMAC10.html)
WO (1) WO2001093905A1 (cg-RX-API-DMAC10.html)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
HU228264B1 (en) * 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
EP1347775B1 (en) 2001-01-05 2016-11-30 Valneva Austria GmbH Uses for polycationic compounds as vaccine adjuvants
US20040081655A1 (en) * 2001-01-05 2004-04-29 Karen Lingnau Methods and compositions comprising polycationic compounds
WO2002053184A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
WO2002053185A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1390494A2 (en) * 2001-05-21 2004-02-25 Intercell AG Method for stabilising of nucleic acids
EP1412390A2 (en) * 2001-07-26 2004-04-28 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20050250716A1 (en) * 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP1537418A2 (en) 2002-09-13 2005-06-08 Intercell AG Method for isolating hepatitis c virus peptides
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー B群連鎖球菌の接着因子をコードする核酸、b群連鎖球菌の接着因子、およびその使用
CN1756843B (zh) 2003-03-04 2012-03-21 英特塞尔股份公司 化脓链球菌抗原
ES2351489T3 (es) * 2003-03-24 2011-02-07 Intercell Ag Vacunas mejoradas.
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
AU2004226262A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
EP1620460A2 (en) 2003-05-07 2006-02-01 Intercell AG Streptococcus agalactiae antigens i + ii
EP1629005A2 (en) 2003-05-30 2006-03-01 Intercell AG Enterococcus antigens
CA2530062A1 (en) * 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
JP4817599B2 (ja) * 2003-12-25 2011-11-16 独立行政法人科学技術振興機構 免疫活性増強剤とこれを用いた免疫活性の増強方法
KR100721928B1 (ko) * 2004-11-05 2007-05-28 주식회사 바이오씨에스 CpG 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
DK1931379T3 (da) 2005-10-07 2013-08-19 Sec Dep For Health Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
KR20090024292A (ko) 2006-06-28 2009-03-06 스태튼스 세룸 인스티튜트 단백질 단편 또는 펩타이드 혼합물로서 전달되는 항원을 가진 백신접종에 의해 준우성 항원결정기를 포함하는 t세포 레퍼토리 확장
EP2292647A3 (en) 2006-07-07 2011-06-08 Intercell AG Small Streptococcus pyogenes antigens and their use
EP2289906A1 (en) 2006-09-15 2011-03-02 Intercell AG Borrelia antigens
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2266592A3 (en) 2007-01-12 2012-08-08 Intercell AG Protective proteins of S. agalactiae, combinations thereof and methods of using the same
CA2685805A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
EP2158211B1 (en) 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
EP2511291A3 (en) 2007-06-18 2012-11-07 Intercell AG Chlamydia antigens
AU2009226949A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
WO2009155484A2 (en) 2008-06-20 2009-12-23 Wyeth Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
EP2424882A2 (en) 2009-02-05 2012-03-07 Intercell AG Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
EP2319871A1 (en) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
PH12012500564A1 (en) 2009-10-09 2012-10-22 Sanofi Sa Polypeptides for binding to the receptor for advanced glycation endproducts as well as compositions and methods involving the same
EP2308896A1 (en) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EP3626263A1 (en) 2010-06-04 2020-03-25 Wyeth LLC Vaccine formulations
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
AR082925A1 (es) 2010-09-08 2013-01-16 Medigene Ag Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
HUE033072T2 (hu) 2010-12-22 2017-11-28 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
JP5872684B2 (ja) * 2011-05-26 2016-03-01 インターベット インターナショナル ベー. フェー. 免疫刺激性オリゴデオキシヌクレオチド
US9315814B2 (en) * 2011-05-26 2016-04-19 Intervet Inc. Immunostimulatory oligodeoxynucleotides
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
RU2672053C2 (ru) 2012-12-20 2018-11-09 Пфайзер Инк. Способ гликоконъюгации
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
CN106488929B (zh) * 2014-05-09 2021-08-24 乌得勒支大学控股有限公司 新型cath2衍生物
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
KR102143534B1 (ko) 2015-05-04 2020-08-12 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
EP3527223A1 (en) 2018-02-16 2019-08-21 2A Pharma AB Mutated parvovirus structural protein
CN112074295A (zh) 2018-02-16 2020-12-11 2A制药公司 用于治疗自身免疫性疾病的细小病毒结构蛋白
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신
WO2020240268A1 (en) 2019-05-31 2020-12-03 Universidad De Chile An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021211279A1 (en) 2020-04-17 2021-10-21 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
EP4203995A1 (en) 2020-08-26 2023-07-05 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2022074061A1 (en) 2020-10-07 2022-04-14 Valneva Sweden Ab Cholera vaccine formulation
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine
KR20250054810A (ko) 2022-09-29 2025-04-23 화이자 인코포레이티드 Rsv f 단백질 삼량체를 포함하는 면역원성 조성물
WO2026038177A1 (en) 2024-08-16 2026-02-19 Pfizer Inc. Immunogenic compositions and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
WO1990014424A1 (en) * 1989-05-16 1990-11-29 Scripps Clinic And Research Foundation Method for isolating receptors having a preselected specificity
WO1992011389A1 (en) * 1990-12-21 1992-07-09 F. Hoffmann-La Roche Ag Hla dqbeta dna typing
US5691136A (en) 1991-10-23 1997-11-25 Baylor College Of Medicine Fingerprinting bacterial strains using repetitive DNA sequence amplification

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725545A (en) 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
ZA908001B (en) * 1989-10-11 1991-08-28 Merrell Dow Pharma Inosine/guanosine derivatives as immunosuppressive agents
US5514577A (en) * 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5098437A (en) * 1991-02-13 1992-03-24 Pfizer Hospital Products Group, Inc. Acetabular cup positioning insert
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US20020081577A1 (en) * 1995-06-06 2002-06-27 Robert L. Kilkuskie Oligonucleotides speciific for hepatitis c virus
ZA964446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
ES2168472T3 (es) * 1995-06-06 2002-06-16 Beth Israel Hospital Procedimiento y aparato para ensayo diagnostico de adn.
AU736785B2 (en) * 1996-10-02 2001-08-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Detection and identification of non-polio enteroviruses
WO1998016247A1 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
WO1998055609A1 (en) 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
US5955443A (en) * 1998-03-19 1999-09-21 Isis Pharmaceuticals Inc. Antisense modulation of PECAM-1
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
IL126919A0 (en) * 1998-11-05 1999-09-22 Univ Ben Gurion Antisense oligomer
AU765940B2 (en) * 1998-06-24 2003-10-02 Innogenetics N.V. Particles of HCV envelope proteins: use for vaccination
WO2001022972A2 (en) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
AU2001257366B2 (en) 2000-05-01 2006-03-16 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
HU228264B1 (en) * 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AU2004224746B2 (en) * 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
US7951845B2 (en) * 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
WO1990014424A1 (en) * 1989-05-16 1990-11-29 Scripps Clinic And Research Foundation Method for isolating receptors having a preselected specificity
WO1992011389A1 (en) * 1990-12-21 1992-07-09 F. Hoffmann-La Roche Ag Hla dqbeta dna typing
US5691136A (en) 1991-10-23 1997-11-25 Baylor College Of Medicine Fingerprinting bacterial strains using repetitive DNA sequence amplification

Also Published As

Publication number Publication date
NO20025835L (no) 2002-12-04
TR200302015T4 (tr) 2004-01-21
RU2007103151A (ru) 2008-08-20
AU2001281812B2 (en) 2005-04-07
BR0111639A (pt) 2003-03-25
IL152959A (en) 2008-04-13
PT1296713E (pt) 2004-02-27
CN1309418C (zh) 2007-04-11
US8945591B2 (en) 2015-02-03
MXPA02012010A (es) 2005-04-22
HUP0301229A3 (en) 2010-01-28
BRPI0111639B8 (pt) 2021-05-25
IL152959A0 (en) 2003-06-24
KR20030032964A (ko) 2003-04-26
US20130183339A1 (en) 2013-07-18
CZ304195B6 (cs) 2013-12-27
HK1056678A1 (en) 2004-02-27
WO2001093905A1 (en) 2001-12-13
ES2206424T3 (es) 2004-05-16
DE60100814D1 (de) 2003-10-23
IS6627A (is) 2002-11-18
CA2411575C (en) 2015-04-07
BRPI0111639B1 (pt) 2017-04-11
CZ20024168A3 (cs) 2003-09-17
SK287689B6 (sk) 2011-06-06
IS1993B (is) 2005-03-15
US20150125488A1 (en) 2015-05-07
JP5908851B2 (ja) 2016-04-26
JP5271471B2 (ja) 2013-08-21
ATE249839T1 (de) 2003-10-15
PL358982A1 (pl) 2004-08-23
PL211036B1 (pl) 2012-04-30
SK18152002A3 (sk) 2003-08-05
RU2413520C2 (ru) 2011-03-10
RU2293573C2 (ru) 2007-02-20
AU8181201A (en) 2001-12-17
NO329492B1 (no) 2010-11-01
CA2411575A1 (en) 2001-12-13
EP1296713B1 (en) 2003-09-17
DE60100814T2 (de) 2004-07-01
DK1296713T3 (da) 2004-01-26
US8568742B2 (en) 2013-10-29
HU228264B1 (en) 2013-02-28
CN1434723A (zh) 2003-08-06
US9492537B2 (en) 2016-11-15
HUP0301229A2 (hu) 2003-08-28
SI1296713T1 (en) 2004-02-29
US20030171321A1 (en) 2003-09-11
NO20025835D0 (no) 2002-12-04
EP1296713A1 (en) 2003-04-02
JP2013121962A (ja) 2013-06-20
JP2003535146A (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
AU2001281812B2 (en) Immunostimulatory oligodeoxynucleotides
US7858588B2 (en) Immunostimulatory oligodeoxynucleic molecules
AU784403B2 (en) Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants
ZA200209479B (en) Immunostimulatory oligodeoxynucleotides.
AU2001281812A1 (en) Immunostimulatory oligodeoxynucleotides
AU2002320762A1 (en) Immunostimulatory oligodeoxynucleic molecules

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20021207

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20021223

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060601

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070424

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20071120

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20080124

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20080124

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20110118

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20120117

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130114

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130114

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20140117

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20140117

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20150116

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20150116

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20160119

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20160119

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20170113

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20170113

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20180112

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20180112

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20210115

Start annual number: 14

End annual number: 14

PC1801 Expiration of term

Termination date: 20211207

Termination category: Expiration of duration